XLRN stock news

Acceleron Pharma's (XLRN) pipeline candidate, ACE-083, fails to translate muscle volume growth into improvements in functional tests in FSHD patients. Acceleron discontinues development. Read more
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 16) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR )( announced a deal to be bought by Danish pharma company Lundbeck) AxsomeTherapeutics Inc (NASDAQ: AXSM ) Kodiak Sciences Inc (NASDAQ: KOD )(announced positive emerging durability data from a Phase 1b study of its pipeline asset KSI-301 in wet age-related macular degeneration) The Medicines Company (NASDAQ: MDCO ) Natera Inc (NASDAQ: NTRA ) -mAbs Therapeutics, Inc (NASDAQ: YMAB ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 16) BioNano Genomics Inc (NASDAQ: BNGO ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Myovant Sciences Ltd (NYSE: MYOV ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Acceleron To Discontinue Development Of Mid-Stage Asset To Treat Muscular Dystrophy Acceleron Pharma Inc (NASDAQ: XLRN ) said it's halting the development of ACE-083 as a treatment option for patients with facioscapulohumeral muscular dystrophy. Read more
Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type… Read more
The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up. Read more
Cambridge, Massachusetts-based Acceleron Pharma Inc (NASDAQ: XLRN ) said Monday that the FDA has accorded Orphan Drug Designation to its sotatercept . The drug is an investigational asset to treat pulmonary arterial hypertension, or PAH. Sotatercept is a selective ligand trap for members of the TGF-beta superfamily to rebalance BMPR2 signaling, which is a key driver of PAH. An ODD is granted by the … Full story available on Benzinga.com Read more
Acceleron (XLRN) delivered earnings and revenue surprises of -41.67% and 1.95%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock? Read more
XLRN earnings call for the period ending March 31, 2019. Read more
Acceleron Pharma, Inc. (NASDAQ:XLRN) Q1 2019 Earnings Conference Call May 9, 2019, 5:00 pm ET Company Participants Todd James - VP, IR & Corporate Communica Read more

Proudly made at